Roggwil, April 28, 2020 – In May 2020, Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, will have the securitization of the shares in sight deposit custody canceled. After the shares have been booked from the custody accounts of the investors, they can request a physical share certificate from the company with the last custody account statement.
Nothing will change for shareholders who already have a physical share certificate.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. The shares have been traded on the Vienna Stock Exchange in the Vienna MTF segment since June 2018. Resaphene Deutschland GmbH in Constance and Resaphene UK Ltd. in London and Resaphene US LLC in the US act as further sales companies.
++ Contact for questions:
Resaphene Suisse AG
Investor Relations contact:
Ms. Anke Rauterkus (Chief Executive Officer)